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Abstract
Salmeterol is a partial agonist for the β2 adrenergic receptor (β2AR), and the first long-acting 
β2AR agonist (LABA) to be widely used clinically for the treatment of asthma and chronic 
obstructive pulmonary disease. Salmeterol has been controversial both for its safety and 
mechanism of action. To understand its unusual pharmacological action and partial agonism, we 
obtained the crystal structure of salmeterol-bound β2AR in complex with an active-state 
stabilizing nanobody. The structure reveals the location of the salmeterol exosite, where sequence 
differences between β1AR and β2AR explain the high receptor subtype selectivity. A structural 
comparison with the β2AR bound to the full agonist epinephrine reveals differences in the 
hydrogen bond network involving residues Ser 2045.43 and Asn 2936.55. Mutagenesis and 
biophysical studies suggest that these interactions lead to a distinct active-state conformation that 
is responsible for the partial efficacy of G protein activation and the limited β-arrestin recruitment 
for salmeterol.
Introduction
G-protein coupled receptors (GPCRs) are able to respond to a large variety of ligands with 
different efficacy profiles for specific signaling pathways1: full agonists that maximally 
stimulate; partial agonists that produce submaximal stimulation even at fully saturating 
concentrations; inverse agonists that suppress the basal signaling; and neutral antagonists 
that bind to the receptor without stimulating or inhibiting basal signaling. Among these 
categories, partial agonists are often better tolerated as therapeutics compared with full 
agonists2.
Salmeterol is a partial agonist for the human β2-adrenergic receptor (β2AR). As a potent 
bronchodilator, it is among the most prescribed drugs for the treatment of asthma and 
chronic obstructive pulmonary disease (COPD)3. Compared to some other β2AR agonists 
such as isoproterenol and salbutamol, salmeterol exhibits two desirable pharmacological 
properties. First, salmeterol is able to distinguish β2AR from β1AR for selective stimulation 
(1400- to 3000-fold selectivity)4, thereby minimizing cardiac toxicity5. Second, salmeterol 
belongs to the class of long-acting β2AR agonists (LABAs) with a duration of action up to 
12 hours, in contrast to the short-acting β2AR agonists such as salbutamol with only a 4–6 
hour duration of action6–8. Those pharmacological properties of salmeterol have contributed 
to its successful use in treating asthma and COPD for more than two decades. However, 
LABAs used alone, especially salmeterol, have been implicated, in several clinic trials, to be 
associated with increased mortality in asthmatics. This liability is mitigated when LABAs 
are combined with an inhaled corticosteroid9–11.
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The high selectivity and long-acting properties of salmeterol have been attributed to its 
unusual bitopic structure. In addition to the saligenin ethanolamine pharmacophore that 
replaces the catecholamine structure of the endogenous β2AR ligand epinephrine (also 
known as adrenaline), salmeterol contains an extra moiety of an aryloxyalkyl tail consisting 
of a phenol ring with an eleven-atom ether chain (Fig. 1a). While the pharmacophore binds 
to the orthosteric site responsible for receptor activation, the aryloxyalkyl tail is proposed to 
bind to an additional site (exosite), providing additional interactions responsible for the high 
receptor-subtype selectivity and the slow dissociation rate contributing to its long duration of 
action12. Previous mutagenesis and biochemical studies to locate the exosite have led to 
conflicting results4,12–16. Salmeterol is also of interest in being a functionally selective 
β2AR partial agonist with a 5- to 20-fold bias towards Gs over arrestin17,18. Previous studies 
revealed that, compared to isoproterenol, activation of the β2AR by salmeterol leads to 
slower initial rates of G protein-coupled receptor kinase (GRK) phosphorylation with similar 
maximal degrees of phosphorylation19,20, but strongly reduced arrestin-mediated receptor 
internalization and desensitization17,21,22, contributing to the prolonged therapeutic effect of 
salmeterol in bronchial dilation as a result of β2AR stimulation. This signaling bias may 
contribute to the advantageous therapeutic profile of salmeterol by maintaining 
bronchodilation through Gs-mediated signaling while minimizing arrestin-mediated β2AR 
desensitization, and avoiding arrestin-dependent pro-inflammatory effects23,24.
Recent progresses in the structural characterization of β adrenergic receptors, especially the 
crystal structures of active β2AR bound to full agonists BI-167107 or epinephrine (also 
known as adrenaline), with either a Gs protein or active-state stabilizing nanobody, as well 
as the crystal structures of inactive avian β1AR bound to a variety of full and partial 
agonists, have greatly advanced our understanding of the pharmacology and activation of β 
adrenergic receptors25–29. In an effort to further understand the molecular basis for the 
unusual pharmacological properties of salmeterol and its partial agonism, we obtained the 
crystal structure of salmeterol-bound human β2AR in an active state stabilized by a 
conformation-specific nanobody, Nb71. The structure reveals the location of the exosite and 
provides a structural explanation for the high receptor-subtype selectivity and distinct 
signaling behavior of salmeterol.
Results
Nanobody Nb71 stabilizes the salmeterol-bound β2AR
It has been shown for the β2AR and the μ-opioid receptor (μOR) that agonists alone are not 
sufficient to stabilize the receptors in active conformational states27,30–32. As a result, the 
active-state structures of the β2AR and μOR have required either a G protein or 
conformation-specific camelid antibody fragments (nanobodies) to stabilize the active states 
of the receptors25,26,29. The first active-state structure of a hormone-activated GPCR was 
obtained using a nanobody named Nb80, which was obtained from a llama immunized with 
β2AR bound to the ultra high-affinity full agonist BI-167107 reconstituted into phospholipid 
vesicles25. The structures of β2AR in the β2AR-Nb80 complex and the β2AR-Gs complex 
are very similar25,26. However, evidence from biophysical studies suggest that partial 
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agonists may stabilize distinct states33, so Nb80 may not be the best candidate to stabilize 
salmeterol-bound β2AR.
While Nb80 preferentially binds to agonist-occupied β2AR over antagonist-occupied 
β2AR25, Octet Red studies show that Nb80 also preferentially binds to β2AR bound to 
BI-167107 and epinephrine over β2AR bound to salmeterol (Supplementary Table 1). 
Moreover, Nb80 has a greater effect on enhancing the binding affinity of the agonist 
isoproterenol than on the partial agonist salmeterol (Supplementary Fig. 1). We therefore 
selected another nanobody, Nb71, generated from the same immunization that produced 
Nb80. Nb71 preferentially binds to agonist-occupied β2AR34, but in contrast to Nb80, has 
no preference for these catecholamines over salmeterol (Supplementary Table 1, 
Supplementary Fig. 1). Therefore, we chose Nb71 to stabilize the salmeterol-bound β2AR 
for structural characterization.
Structural features of Nb71-stabilized β2AR
We used an engineered β2AR with T4 lysozyme (T4L) fused to its N-terminal region and a 
truncated intracellular loop3 (referred to as T4L-β2AR-ΔICL3 hereafter) to crystallize β2AR 
bound to salmeterol. Previous studies have demonstrated that T4L-β2AR-ΔICL3 exhibits 
similar ligand binding and G protein activating properties as the wild type β2AR37. Using 
this construct, we obtained crystals of the β2AR-salmeterol-Nb71 complex by the lipidic 
cubic phase (LCP) method35. A complete data set was obtained by merging data from 23 
crystals and the structure was determined to a resolution of 3.0 Å (Fig. 1b,c; Supplementary 
Table 2). Like Nb80, Nb71 binds to the cytoplasmic surface of the receptor with its third 
complementarity-determining region (CDR3) loop inserted into a hydrophobic cavity 
formed by residues from transmembrane helices (TMs) 3, 5, 6 and 7 (Fig. 1b, 
Supplementary Fig. 2), yet Nb71 stabilizes a conformation that is distinct from that 
stabilized by Nb80 (Supplementary Fig. 2).
The active-state conformation of the receptor in the β2AR-salmeterol-Nb71 complex 
resembles that of the BI-167107-bound β2AR in complex with Nb80 (PDB ID 3P0G, rmsd = 
1.0 Å) or with Gs (PDB ID 3SN6, rmsd = 1.3 Å) more than the inactive-state conformation 
of the receptor in the inverse agonist carazolol-bound β2AR structure (PDB ID 2RH1, rmsd 
= 1.9 Å)25,26. Indeed, the structural features associated with receptor activation25, including 
the outward movement of TM6 at the cytoplasmic side associated with the conformational 
changes of the core triad residues Pro 2115.50, Ile 1213.40 and Phe 2826.44, as well as the 
slightly contracted ligand-binding pocket at the extracellular side, are all observed in the 
structure of β2AR-salmeterol-Nb71 complex when compared to the inactive β2AR (Fig. 2a-
c). However, the Nb71-stabilized β2AR shows some distinct structural features compared to 
the Nb80- and Gs-stabilized β2AR. Relative to the inactive β2AR, the Nb71-stabilized β2AR 
displays a smaller outward movement of the cytoplasmic end of TM6 (8Å) than the Nb80-
stabilized β2AR (11Å) or Gs-stabilized β2AR (13Å) (Fig. 2a). There is also a slightly 
smaller counter-clockwise rotation of TM6 in the Nb71-stabilized β2AR when viewed from 
the cytoplasmic surface, as shown by the position of Glu268 (Fig. 2b). While this current 
structure clearly shows an active-state conformation of β2AR, the smaller conformational 
rearrangements observed for TM6 upon activation compared to the changes seen for the 
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active-state stabilized β2AR bound to Nb80 or Gs suggest a less active or a partially active 
conformational state of β2AR stabilized by Nb71. It is tempting to speculate that such 
partially active conformational state may closely resemble a salmeterol-stabilized 
conformation of β2AR that is less efficient at coupling to Gs. However, the conformation of 
TM6 is primarily stabilized by interactions with Nb71 and may not reflect the conformation 
stabilized by salmeterol alone.
Exosite binding of salmeterol
The location and the molecular details of the exosite for the aryloxyalkyl tail of salmeterol 
are of great interest because of its association with the high receptor selectivity, high affinity 
and long-lasting action properties of salmeterol. The clear electron density map of 
salmeterol based on our structure allowed us to unambiguously define the structural basis of 
the exosite (Figs. 3a,b & Supplementary Figs. 3,4). The crystal structure shows that the 
aryloxyalkyl tail of salmeterol extends towards the extracellular surface of the receptor, 
occupying a cleft formed by residues from extracellular loop2 (ECL2), ECL3 and the 
extracellular ends of TM6 and TM7. Interactions between salmeterol and the exosite are 
mediated primarily through extensive van der Waals and hydrophobic interactions (Fig. 3c). 
The phenol ring of the tail also forms π-π interactions with the surrounding aromatic 
residues Phe 194ECL2, Tyr 3087.35 and His 2966.58 (Ballesteros-Weinstein numbers), in 
agreement with previous studies reporting a 5- to 18-fold decrease of salmeterol affinity 
caused by mutating those residues4. In addition, the ether oxygen atom of the tail forms a 
hydrogen bond with the main chain amide group of residues Phe 193 ECL2 (Fig. 3a). It acts 
as a ‘hinge’ point where the tail of salmeterol bends almost 90° to fit the exosite. Previous 
studies indicated that shifting the ether oxygen in the aryloxyalkyl tail or removing it 
substantially reduces the affinity of salmeterol for β2AR21, suggesting an important role of 
this hydrogen bond in the exosite binding (Supplementary Fig. 5). All those additional 
interactions in the exosite contribute to the 1000-fold higher affinity of salmeterol compared 
to salbutamol, a short-acting β2AR agonist (SABA) which shares the same orthosteric 
pharmacophore as salmeterol but lacks the long aryloxyalkyl tail36 (Fig. 1a).
The exosite binding also explains the very high selectivity of salmeterol for β2AR over 
β1AR (>3000-fold)36. β1AR and β2AR share a very high overall structural similarity (rmsd 
of carazolol-bound avian β1AR and human β2AR = 0.58 Å, PDB IDs 2YCW & 2RH1, 
respectively) and sequence similarity (92% in TM segments for human β1AR and β2AR, 
Supplementary Fig. 6). In particular, all residues that form the orthosteric binding pocket, 
with the exception of Y308 are identical in β1AR and β2AR. In contrast, the exosite is 
relatively divergent in those two receptors. Salmeterol achieves high receptor selectivity by 
sampling this divergent region with its long aryloxyalkyl tail (Fig. 3d, Supplementary Fig. 
6). Such selectivity determinants do not apply to salbutamol, which only has about 20-fold 
selectivity for β2AR over β1AR36. Our results are in agreement with extensive chimeric 
receptor and site-directed mutagenesis studies recently reported by Baker et al.7, who 
observed the K305D and H296K mutations in the β2AR to have a substantial effect on 
salmeterol affinity while having little effect on salbutamol affinity.
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The salmeterol exosite in β2AR is reminiscent of the well-defined allosteric site in the M2 
muscarinic receptor (M2R)37. The M2R represents one of the most extensively characterized 
model systems for allosteric regulation. Fig. 3e shows a comparison of the exosite in the 
β2AR and the binding site for the positive allosteric modulator LY2119620 revealed by the 
active-state crystal structure of M2R bound to the orthosteric agonist iperoxo and 
LY211962037. The similarity between those two sites suggests the potential for allosterically 
regulating β2AR activity by small molecules that target the exosite. On the other hand, the 
bitopic nature of salmeterol with two-site binding on β2AR supports the feasibility of 
developing highly selective bitopic compounds for other GPCRs including muscarinic 
receptors38.
Polar interactions within the orthosteric binding site
While the interactions between the aryloxyalkyl tail of salmeterol and the exosite in the 
extracellular vestibule of β2AR confer the high affinity and selectivity of salmeterol, they are 
not responsible for its efficacy and signaling bias. Salmeterol and salbutamol exhibit similar 
signaling properties including partial agonism and the selective activation of Gs over arrestin 
and Gi (Supplementary Fig. 7)17, despite their differences in affinity and receptor selectivity. 
Considering that salmeterol and salbutamol only share the saligenin ethanolamine 
pharmacophore (Fig. 1a), the interactions between this shared pharmacophore and the 
receptor within the orthosteric binding pocket are likely to be responsible for their shared 
signaling properties. In the orthosteric binding site, the alkylamine and β-hydroxyl groups of 
salmeterol form hydrogen-bonding interactions with Asp 1133.32 and Asn 3127.39 and the 
saligenin group forms hydrogen-bonding interactions with Ser 2035.42 and Ser2075.46, 
similar to those observed for β2AR bound to the full agonist epinephrine (Figs. 4a,b). In the 
structure of β2AR bound to epinephrine, the hydrogen bonding interactions with Ser 2035.42 
and Ser2075.46 are associated with the inward movement of TM5 around those two serine 
residues, which is further linked to the rearrangement of the core triad residues and the 
outward movement of the cytoplasmic end of TM629. For salmeterol, the two saligenin 
hydroxyl groups also form direct hydrogen bonding interactions with Ser 2035.42 and Ser 
2075.46. However, compared to epinephrine, these interactions with salmeterol may have a 
weaker effect on stabilizing the inward movement of TM5 because of the additional 
methylene between the meta position hydroxyl group and the phenyl ring.
In epinephrine-bound β2AR, Asn 2936.55 forms a hydrogen bond with Ser 2045.43 and the 
meta-hydroxyl of epinephrine. This polar network is not observed in salmeterol-bound 
β2AR. Asn 2936.55 and Ser 2045.43 have previously been shown to be important for the 
binding of epinephrine but not for the binding of antagonists39,40. To further investigate the 
possible role of these polar networks in ligand efficacy, we used molecular dynamics 
simulations to characterize the stability of specific ligand-receptor hydrogen bonds that 
would be expected to stabilize the inward movement of TM5 and the rotation of TM6 
observed in active state structures of the β2AR (Fig. 5a). These simulations show that 
salmeterol forms less stable hydrogen bonds with Asn2936.55 and Asn3127.39 than does 
epinephrine. Salmeterol forms a more stable hydrogen bond with Ser2035.42, but apparently 
only because its longer hydroxymethyl group can maintain this hydrogen bond better than 
epinephrine’s hydroxyl group even when TM5 moves away from its crystallographic 
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position. Thus, while the salmeterol-bound crystal structure captured a binding pocket 
conformation similar to that observed for full agonist, molecular dynamics simulations 
suggest that this active conformation is stabilized less by salmeterol than by epinephrine, 
with the most dramatic difference observed for Asn2936.55. To further characterize the role 
of Asn 2936.55 and Ser 2045.43 interactions, we examined the effects of mutating these 
residues on β-arrestin2 recruitment and Gs activation by bioluminescence resonance energy 
transfer (BRET) between membrane anchored GFP and luciferase-tagged arrestin or 
luciferase-tagged Gs and GFP-tagged Gβ1/Gγ1, respectively41,42(Fig. 5b,c & Supplementary 
Table 3). For all the mutations we tested in the presence of isoproterenol, a catecholamine 
similar to epinephrine, we observe a dramatic reduction in β-arrestin2 recruitment (Fig. 5b, 
left panel), and a more moderate reduction in Gs activation (Fig. 5c, left panel). This 
suggests an important role of these two residues in regulating bias, either by directly 
modulating arrestin coupling, or by altering GRK phosphorylation and hence arrestin 
binding. Interestingly, the same mutations, with the exception of S204T, had a less 
pronounced effect on the ability of salmeterol to activate Gs (Fig. 5c, right panel), and all 
mutants showed very little or no salmeterol-induced arrestin recruitment, similar to wild-
type β2AR (Fig. 5b, right panel). Thus, the absence of the hydrogen bonds between Asn 
2936.55 and salmeterol may account for the weak β-arrestin recruitment, as well as the lower 
efficacy in Gs activation of salmeterol-bound β2AR compared to β2AR bound to full 
agonist.
Spectroscopic insights into salmeterol-bound β2AR
The differences in efficacy and signaling bias between salmeterol and the full agonist 
epinephrine suggest that salmeterol may stabilize a distinct conformation. Previous single 
molecule Förster resonance energy transfer (FRET) studies suggested a smaller outward 
displacement of TM6 in β2AR bound to salmeterol compared to β2AR bound to epinephrine 
or BI16710743. In addition, cellular assays using a BRET-based β2AR conformational 
sensor44 confirmed the reduced propensity of salmeterol to promote the outward movement 
of TM6 (Supplementary Fig. 8). Nevertheless, these RET studies cannot distinguish the 
following two mechanistic possibilities: 1- salmeterol stabilizes the same conformation of 
TM6 as epinephrine, but for a smaller receptor population; 2- salmeterol stabilizes a distinct 
TM6 conformation. To further investigate the differences at the cytoplasmic end of TM6 
upon activation between salmeterol-bound and epinephrine-bound β2AR in the absence of 
conformation-stabilizing nanobodies, we performed steady-state spectroscopic studies on 
purified, labeled receptor in detergent with two different reporter systems (Supplementary 
Fig. 9a). We used β2AR labeled at Cys 265 with the fluorophore monobromobimane (mBBr 
or bimane), which we previously used as a conformational reporter of β2AR activation31,45, 
and developed a new fluorescent reporter system using an engineered β2AR labeled at 
residue 266 with the fluorophore Atto655.
The bimane fluorophore has been extensively used to report on activation of β2AR25,45,46 as 
well as other GPCRs47,48, as it is very sensitive to its chemical environment. In the inactive 
state, bimane attached at the cytoplasmic end of TM6 is in a hydrophobic environment. 
Upon receptor activation, the intracellular end of TM6 undergoes an outward and 
“unwinding” motion (Fig. 6a) that shifts bimane to a more polar and solvent-exposed 
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environment, resulting in a decrease in fluorescence intensity and a red-shift in λmax. 
Agonists alone produce a 10–20% decrease in intensity and ∼10 nm red-shift in λmax. 
Further changes are observed upon G protein coupling. Using this reporter system, we find 
that even though salmeterol has a higher binding affinity to β2AR than epinephrine6, 
epinephrine causes a larger reduction in intensity and red-shift in λmax of bimane compared 
to salmeterol when both ligands are used at saturating concentrations (Fig. 6b). This 
suggests that salmeterol stabilizes β2AR in conformations with on average a smaller outward 
movement or rotation of TM6. In addition, we observe that Gs induces a similar bimane 
response with salmeterol as with epinephrine (Fig. 6b, “+Gs” curves), indicating that once 
coupled to Gs, the β2AR adopts a similar TM6 conformation no matter what agonist is 
bound at the extracellular region, consistent with previous single molecule FRET studies33. 
Nevertheless, the extent to which salmeterol-bound receptor couples to Gs appears to be 
slightly lower, as the change in λmax and fluorescence intensity is slightly less pronounced 
compared to epinephrine-bound receptor.
To complement the bimane-based measurements, we developed a new, distance-sensitive 
fluorescent reporter. Rather than relying on FRET, where stoichiometric and specific 
labeling of donor and acceptor is required to faithfully report on distance changes in bulk 
measurements, we employed a single-dye reporter system. In photo induced electron transfer 
(PET), fluorophores such as Atto655 can be quenched by a tryptophan in close proximity, 
through the formation of weakly fluorescent or non-fluorescent dye-tryptophan ground-state 
complexes49 (Fig. 6c). Owing to the strong distance-dependence of PET, small-scale 
conformational changes result in “on–off” switching of fluorescence, yielding a change in 
fluorescence intensity but no shift in λmax over a small distance range, typically about 5–
10Å49.
To report only on the outward motion of TM6, we chose to label Leu 266 mutated to 
cysteine instead of the native Cys 265, as the former does not undergo inward to outward 
rotations upon activation, but points outwards in both active and inactive structures 
(Supplementary Fig. 9a). Based on the inactive and active β2AR crystal structures and dye 
simulations (Supplementary Fig. 9b), we speculated that a tryptophan residue introduced at 
the intracellular end of TM5 (L230W) would quench the fluorescence of Atto655 in the 
inactive, but considerably less in the active state, as the distance range and change between 
TM5 and TM6 that occurs upon activation should be compatible with PET-induced 
quenching. By simulating the conformational ensembles of Atto655 bound to Cys 266 in the 
inactive and active β2AR structures, we found an average dye-Trp 230 distance change of 
about ∼5 Å upon receptor activation (Supplementary Fig. 9b), compatible with the reported 
quenching distance. We thus introduced mutations L230W and L266C into a minimal 
cysteine background β2AR33 and verified that the detergent-purified, Atto655-labeled 
β2ARΔ6 L230W:L266C construct retained wild-type ligand binding properties 
(Supplementary Fig. 10).
When measuring the steady-state fluorescence emission of Atto655-labeled β2ARΔ6 
L230W:L266C, referred to as Atto-β2AR from here on, in the presence of saturating 
concentrations of epinephrine, we observe a ∼30% increase in fluorescence intensity 
compared to unliganded receptor, compatible with an outward motion of TM6 and an 
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increased distance between Atto655 and the Trp 230 quencher on TM5 (Fig. 6d, 
Supplementary Fig. 11a). Given the short distance over which PET-quenching occurs, this 
observation likely reflects a TM6 displacement of ∼5Å or more in approximately 30% of 
epinephrine-bound receptor. This is consistent with the fraction of receptor in an active 
conformation observed in double electron-electron resonance spectroscopy studies31. 
Interestingly, we observed a much smaller difference (<10%) between unliganded and 
salmeterol-bound receptor (Fig. 6d, Supplementary Fig. 11a), suggesting that TM6 did not 
move sufficiently far away from TM5 in salmeterol-bound β2AR to reduce Atto655 
quenching by Trp230. Based on the efficacy of salmeterol in G protein activation (60% of 
isoproterenol, Supplementary Fig. 7c) we would expect a much larger change in Atto-β2AR 
fluorescence in response to salmeterol if salmeterol and isoproterenol stabilized the same 
active state. Addition of Gs to salmeterol- and isoproterenol-bound Atto-β2AR led to a 1.8- 
and 2.2-fold increase in fluorescence intensity, respectively, compared to unliganded 
receptor (Fig. 6d, “+Gs” curves). This is consistent with the G protein stabilizing an active 
conformation in a larger fraction of receptor. Control measurements on a construct without 
the engineered L230W mutation showed little intensity change upon addition of agonists 
alone or together with Gs (Supplementary Fig 11b). In line with the difference in TM6 
outward motion between the Nb80- and Nb71-bound structures, the Atto response in the 
presence of Nb80 is much larger than in the presence of Nb71, both for epinephrine and 
salmeterol (Supplementary Fig. 11c). This is similar to what we observed in the presence of 
Gs (Fig. 6b,d): when both ligand and Gs or nanobody are present, the TM6 receptor 
conformation is mainly stabilized by the intracellular binding protein and not the ligand. 
However, both of our fluorescence-based approaches in the absence of nanobody clearly 
suggest a difference in TM6 conformation between epinephrine- and salmeterol-bound 
receptors.
Discussion
β2ARs expressed in airway smooth muscle and epithelial cells mediate bronchodilation and 
fluid clearance, respectively, and are thus well-established targets for the treatment of 
asthma and COPD50. The unusual pharmacological characteristics of salmeterol including 
the extremely high selectivity for β2AR and the long duration of action, which can be 
attributed to its long aryloxyalkyl tail, make it among the most commonly prescribed 
LABAs for treating asthma and COPD. Our structure revealed an additional site in the 
extracellular vestibule of β2AR, the exosite, for the binding of the aryloxyalkyl tail, thus 
providing a structural basis for the prominent pharmacological action of salmeterol. It also 
resolves a long-standing debate as to the location of the exosite.
Our results also provide structural insights into the partial agonism and the biased signaling 
property of salmeterol, which are attributed to its saligenin ethanolamine group bound in the 
orthosteric binding pocket. Although the interactions with the receptor in the orthosteric 
binding pocket are very similar for the full agonist epinephrine and the partial agonist 
salmeterol, we observe subtle differences in hydrogen bonding interactions. Most notable is 
the absence of interactions between salmeterol and Asn 2936.55, which is further supported 
by molecular dynamics simulations. The meta-hydroxyl of epinephrine forms a hydrogen 
bond with Asn 2936.55, which is also hydrogen bonded with Ser 2045.43. Our mutagenesis 
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studies suggest that this hydrogen bond network may be important for stabilizing TM6 in a 
conformation necessary for efficient G protein coupling as well as GRK phosphorylation 
and/or arrestin coupling. Therefore, the less extensive polar interactions between salmeterol 
and Asn 2936.55 may contribute to the weaker efficacy of salmeterol in activating Gs and the 
near absence of β-arrestin recruitment, possibly due to inefficient coupling as a result of 
reduced GRK phosphorylation19.
The structure of salmeterol-bound β2AR revealed a smaller outward movement of TM6 
compared to the epinephrine-bound β2AR. While this conformation implies a ‘partially 
active’ conformation of the receptor, it is likely imposed by the nanobody Nb71 rather than 
by the partial agonist salmeterol. Previous studies have suggested relatively weak allosteric 
coupling between the orthosteric site and the cytoplasmic site31. Thus it is difficult to 
capture the ligand-specific conformation of β2AR by protein crystallography. We took 
spectroscopic approaches using two different reporter systems to interrogate the 
conformational changes of β2AR associated with salmeterol, and showed that indeed TM6 
did not achieve the same extent of outward motion compared to the full agonist epinephrine. 
This correlates with previous single-molecule investigations of TM6 motion in the β2AR33, 
and provides a structural basis for salmeterol’s weaker Gs efficacy and possibly ligand bias. 
Whether this mechanism applies to other GPCRs needs further investigation.
Online Methods
Receptor Constructs
All constructs have an N-terminal Flag tag. The T4L-β2AR-ΔICL3, consists of an N-
terminal T4 lysozyme fusion to β2AR(29–365) ΔICL3, i.e. Δ(235–263) with mutations 
M96T, M98T and N187E. The β2AR-PN1 consists of β2(1–24) – TEV – β2(25–365) – 3C – 
β2(366–413), with “TEV” and “3C” indicating TEV protease and 3C protease cut sites, 
respectively. Additionally, mutations M96T, M98T, C378A, N187E and C406A were 
introduced, as previously described51. The β2ARΔ6 L230W:L266C consists of full-length 
WT receptor with a minimal cysteine background33 (C77V, C265A, C327S, C341L, C378A, 
C406A), as well as mutations L230W and L266C and a C-terminal hexahistidine tag.
Expression, purification and labeling of β2AR constructs
Receptor constructs were expressed in Sf9 insect cell cultures infected with recombinant 
baculovirus (BestBac, Expression Systems), and solubilized in n-dodecyl-β-d-maltoside 
(DDM) according to methods described previously51. The solubilized receptor was purified 
through M1 FLAG chromatography followed by alprenolol-sepharose chromatography to 
remove non-functional receptor51. A second M1 FLAG chromatography was applied such 
that the receptor-bound alprenolol could be removed for unliganded protein or exchanged for 
salmeterol.
For the T4L-β2AR-ΔICL3, after the protein was eluted from the M1 resin, the FLAG epitope 
tag of T4L-β2AR-Δ-ICL3 was removed by the treatment of tobacco etch virus (TEV) 
protease (Invitrogen) for 3h at room temperature or overnight at 4°C. When necessary, a 
50kDa MWCO Vivaspin concentrator (GE Healthcare) was used to concentrate the receptor. 
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The β2AR constructs used for fluorescence studies were concentrated and flash-frozen in the 
presence of 20% glycerol at a final concentration of 200μM. Aliquots were then stored at –
80 °C until use.
Full-length PN1–β2AR was labeled with monobromobimane as previously described52. 
Briefly, FLAG pure receptor (∼2μM) was incubated overnight on ice with 100μM TCEP and 
20μM monobromobimane (Thermo Fisher Scientific). Subsequently, 5mM cysteine was 
added to quench the labeling reaction followed by alprenolol-sepharose chromatography as 
described above. A similar procedure was followed for labeling β2ARΔ6 L230W:L266C 
with Atto655-iodoacetamide (Atto-TEC).
G protein expression and purification
Wild-type Gs heterotrimer was expressed and purified as previously described33. Following 
purification, the protein was dialyzed into 20mM HEPES pH 7.5, 100mM NaCl, 
0.02%DDM, 100μM TCEP and 20μM GDP, concentrated, and flash-frozen in the presence 
of 20% glycerol at a final concentration of 200μM. Aliquots were then stored at –80 °C until 
use.
Preparation of Nb71 and Nb80
The recombinant Nb71 was generated in the same way as Nb8025. These two nanobodies 
were screened from a same library of single-chain nanobody clones after immunizing a 
llama with purified agonist-bound β2AR reconstituted at high density into phospholipid 
vesicles. Nb71 was expressed in E. coli and purified by nickel affinity chromatography in a 
same manner as Nb8025. The protein was then further purified by cation exchange using a 
Mono-S column (GE Healthcare), loading the protein at 20mM NaCl in 20mM MES pH 6.0 
and eluting with a linear gradient from 50 to 500mM NaCl. In order to minimize severe 
precipitation of Nb71 over time, the purified protein was stored at a concentration below 5 
mg/mL in 20mM Hepes, 1M NaCl.
Crystallization
Salmeterol bound receptor (~40mg/ml) was incubated with a 5.5-fold molar excess of Nb71 
(~50mg/mL) for 1 hour on ice. Size exclusion chromatography was then performed to 
remove free Nb71. The purified complex was concentrated to ~60mg/mL for crystallization 
using the lipid cubic phase (LCP) method as previously described35. The protein complex 
was reconstituted in monoolein containing 10% cholesterol at a 1:1.5 protein to lipid ratio 
(w/w). Reconstituted protein-lipid mixture drops of 30 nL were deposited in each well of a 
96-well glass sandwich plate (Molecular Dimensions). The drop was then overlaid with 
650nL of precipitant and the wells sealed with a glass coverslip. Diffraction-quality crystals 
were grown at 20°C in 31–34% PEG 400, 100mM HEPES pH 7.5, 1% 1,2,3-heptanetriol 
following 3 days of incubation at 20°C.
Data collection, structure determination and analysis
Crystals were harvested and frozen in liquid nitrogen directly without using additional cryo-
protectant. Diffraction data from 24 different crystals were measured using the GM/CA-CAT 
microfocus beam at 23-ID-D (Advanced Photon Source, Argonne National Labs). The data 
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were processed with HKL2000 and the structure solved by molecular replacement using 
Phaser. Further model rebuilding was performed by using Coot and the structure was refined 
with Phenix. The validation of the final structural model was performed using Molprobity. 
The overall MolProbity score is 1.35. For the Ramachandran analysis, 96.8% atoms are in 
Ramachandran favored regions and 3.2% atoms are in Ramachandran allowed regions. Data 
processing and refinement statistics are shown in Supplementary Table 2.
The structure of the inactive β2AR (PDB ID 2RH1), the β2AR complexed with Nb80 (PDB 
ID 3P0G), the β2AR complexed with Gs (PDB ID 3SN6), the chain A of sabultamol bound 
β1AR (PDB ID 2Y04) were used for structural alignments in PYMOL based on Cα only. 
The secondary structure of β2AR ICL2 was assigned by PYMOL and DSSP.
Reconstitution of β2AR in HDL particles for Octet Red measurements
The β2AR was reconstituted in high-density lipoprotein (HDL) particles using established 
methods51. The scaffold protein ApoA-I used for reconstitution was purified as previously 
described51. Purified ApoA-I was biotinylated for 30 min at room temperature using NHS-
PEG4-biotin (Thermo) at a 1:1 molar ratio in a buffer composed of 20 mM HEPES, pH 8.0, 
100mM NaCl, 1mM EDTA, 5 mM sodium cholate. Following the labeling reaction, 
unreacted biotin was quenched by the addition of Tris-HCl, pH 8.0 to a final concentration 
of 20 mM. Biotinylated protein was separated from free biotin by size exclusion 
chromatography on Superdex 75 HR 10/30. FLAG-tagged β2AR was incorporated into HDL 
particles using biotinylated ApoA-I and receptor-containing HDL particles were isolated 
using M1 anti-FLAG immunoaffinity chromatography.
Nanobody binding to β2AR in biotinylated HDL particles was monitored using the 
OctetRED biolayer interferometry system (Pall FortéBio) using streptavidin-coated 
biosensors (Pall FortéBio). Sensors were hydrated for at least 10 min at room temperature in 
assay buffer (20 mM Tris-HCl pH 7.4, 136 mM NaCl, 2.7 mM KCl, 1 mM EDTA, 0.02% 
w/v ascorbic acid, 0.05% w/v BSA), then incubated with biotinylated β2AR-HDL (~100 
nM) for 10 min at room temperature prior to loading the sensors onto the OctetRED 
instrument. All steps on the OctetRED were performed at 25 °C with the assay plate shaking 
at 1,000 rpm. After an initial baseline reading, sensors were dipped into wells containing 
assay buffer with a saturating concentration of agonist (100μM Epinephrine, 0.1μM 
BI-167107, or 1μM Salmeterol) and incubated for 20 min to equilibrate β2AR with agonist. 
The sensors were transferred to wells containing assay buffer plus agonist and nanobody (1, 
3.2, 10, 32, 100, or 320 nM) for 5 min to monitor nanobody association. Nanobody 
dissociation was monitored by then transferring the sensors to wells containing assay buffer 
plus agonist for 30 min. Nonspecific nanobody binding at each concentration was measured 
in a parallel experiment in which sensors were loaded with empty HDL. Buffer-only 
controls were also included in each experiment to correct for baseline drift. Data were first 
analyzed using Octet Data Analysis 7.0 software (Pall FortéBio) to remove baseline and 
nonspecific binding, and the processed data were exported to Prism 6 (GraphPad) for curve 
fitting. All association and dissociation curves were fit using single-phase exponential 
association or decay.
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BRET measurements for Gs activation, β-arrestin recruitment and β2AR conformational 
change in live cells.
HEK293T cells used for the BRET assays were grown in Dulbecco’s modified Eagle’s 
medium (DMEM), supplemented with 10% newborn calf serum (NCS), at 37 ⁰C with 5% 
CO2. Cells were detached with trypsin-EDTA and transfected with 2.5 μg of total DNA per 
106 cells, using linear polyethyleneimine (PEI, Polysciences) as transfecting agent, at a ratio 
of 3:1 (PEI:DNA). Gs activation was evaluated with Gs-117-RLucII/Gβ1/Gγ1-GFP1041 and 
β-arrestin recruitment with CAAX-rGFP/β-arr2-RLucII42 sensors, in presence of WT 3HA-
β2AR or mutant receptors. The conformational changes were detected with the NY-β2AR 
sensor53. Directly after transfection, cells were plated in 96-well white plates (Greiner) at a 
density of 50,000 cells/well, and incubated for 48 h. After that period, the plates were 
washed with PBS and assay buffer (Hank’s balanced salt solution (HBSS)) was added. Cells 
were stimulated with the ligands during 5 or 15 min for evaluating, respectively, Gs 
activation or β-arrestin recruitment and conformational changes. Coelenterazine 400a (2.5 
μM) was added 5 min before the reads. BRET was monitored using a TriStar LB942 
microplate reader (Berthold) equipped with a 410/80 nm donor filter and a 515/40 nm 
acceptor filter (for Gs activation and β-arrestin recruitment) or a 485/20 nm donor filter and 
a 530/25 nm acceptor filter (for receptor conformational changes). BRET ratio was 
calculated by dividing the acceptor emission by the donor emission. The data were analyzed 
with Prism (Graphpad) using “dose-response- stimulation log(agonist) vs normalized 
response- variable slope” with the constraint of sharing the hill slope across all data sets.
Molecular Dynamics Simulations
We simulated the β2-adrenergic receptor bound to the partial agonist salmeterol as well as 
the full agonist epinephrine. We initiated these simulations from crystal structures of the 
receptor bound to each of these ligands. Each of the crystal structures we used includes a 
nanobody that binds to the intracellular side of the receptor and stabilizes an active or 
intermediate receptor state: Nb71 for salmeterol and Nb6B9 for epinephrine29.
We performed three simulations of β2AR–salmeterol–Nb71 and three simulations of β2AR–
epinephrine–Nb6B9. Each of the crystallized constructs was a β2AR–T4 lysozyme (T4L) 
fusion protein, with T4L replacing the receptor’s N-terminus. T4L was omitted from all 
simulations, while all other resolved residues were included. The majority of ICL3 was 
absent in all simulations, because it was deleted from the crystallized construct in β2AR–
salmeterol–Nb71 and β2AR–epinephrine–Nb6B9. Because the simulations were performed 
before the published coordinates had been finalized, they were initiated using coordinates 
that differed very slightly from the published ones (root mean squared deviation below 0.3 
Å, computed over all resolved receptor Cα atoms); these differences were much smaller than 
the typical motions of the atoms in simulation. In all simulations, a palmitoyl group not 
resolved but presumed to be present in the crystallized constructs was added to Cys341 
using Maestro (Schrödinger LLC, New York, NY).
The β2AR was embedded in a hydrated lipid bilayer in all simulations; all atoms (including 
those in lipids and water) were represented explicitly. Hydrogen atoms were added to the 
crystal structures using Maestro, as described previously, and receptor chain termini were 
Masureel et al. Page 13
Nat Chem Biol. Author manuscript; available in PMC 2019 April 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
capped with neutral groups (acetyl and methylamide). Titratable residues other than 
Glu1223.41 were left in their dominant protonation state at pH 7.0. Glu1223.41, which faces 
the lipid bilayer, was neutral (protonated) in all simulations.
Prepared protein structures were inserted into an equilibrated bilayer solvated with 0.15 M 
NaCl, using a previously described protocol54. The bilayer consisted of palmitoyl-oleoyl-
phosphatidylcholine, with 24% palmitoyl-oleoyl-phosphatidylserine in the inner membrane 
leaflet. Simulated systems initially measured roughly 71 × 71 × 115 Å3 and contained 
approximately 140 lipid molecules, 12,000 water molecules, 32 chloride ions, and 40 
sodium ions.
We also performed three simulations of β2AR–salmeterol with the nanobodies removed (but 
otherwise starting from the same structures as above). Simulation setup was as described 
above, except that the removal of the nanobody allowed the simulated volume to be 
somewhat smaller. These simulations initially measured roughly 69 × 69 × 85 Å3 and 
contained approximately 120 lipid molecules, 7200 water molecules, 19 chloride ions, and 
30 sodium ions.
We used the CHARMM-h force field for proteins. We used the CHARMM36 lipid force 
field, along with standard CHARMM salt ion parameters and the CHARMM TIP3P model 
for water. Parameters for palmitoyl-cysteine were as described previously27,54, and 
parameters for epinephrine were obtained by adapting previously published parameters for 
isoproterenol55. Parameters for salmeterol were obtained from the ParamChem server. Full 
parameter sets are available upon request.
Each simulation consisted of a 50-ns equilibration run followed by a longer production run. 
Systems were equilibrated in the NPT ensemble (310 K, 1 bar, Martyna-Tuckerman-Klein 
Nosé-Hoover chain coupling scheme using a multigrator, with initial velocities sampled 
from the Boltzmann distribution and with 5 kcal mol−1 Å−2 harmonic position restraints 
applied to the protein and ligand atoms, which were tapered off linearly over 50 ns. 
Production simulations used the same integrator, pressure and temperature, and were 
initiated from the final snapshot of the corresponding equilibration simulation. All 
simulations were performed on an Anton 1 computer56.
All bond lengths to hydrogen atoms were constrained using M-SHAKE. An r-RESPA 
integrator was used with a time step of 2.5 fs, and long-range electrostatics were computed 
every 7.5 fs. Long-range electrostatics were computed in reciprocal space with the u-series 
method57.
Simulation snapshots were saved every 180 ps. For the purposes of evaluating the fraction of 
time a hydrogen bond was formed in simulation, such a bond was considered to be formed 
in snapshots in which the relevant non-hydrogen atoms were within 3.0 Å of one another. 
Because the bound ligands shifted pose during the later parts of certain simulations (possibly 
as a result of motion of the nanobodies, which are not held in place by crystallographic 
contacts), we used the first microsecond of each simulation for these analyses. Each error 
bar was calculated as standard error of the mean across three simulations.
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Dye modeling
The structure of the iodoacetamide derivative of the Atto655 dye (Atto-TEC GmbH) was 
obtained from PubChem (CID 16218785) and optimized using Avogadro and the GAFF 
force field. The structures of β2AR in the active (PDB ID 3SN6) and inactive conformations 
(PDB ID 2RH1) were retrieved from the RCSB PDB and mutated (L230W and L266C) 
using PyMOL. Parameters for the dye molecule attached to a cysteine residue were obtained 
using PRODRG and manually edited to enforce planarity of the ring system of the dye. The 
Crystallography and NMR System (CNS) software, version 1.358, was used to attach the dye 
to L266C and simulate its positions using rigid-body docking and multi-trial simulated 
annealing, respectively, as done previously by Brunger and co-workers59. The entire receptor 
structure was kept rigid, except for the side-chain atoms of L230W and L266C. Distances 
between the centers of mass of the tryptophan side-chain atoms and center of mass of the 
ring system of the dye were calculated for each generated model (300 for each conformation 
of β2AR).
Fluorescence measurements on purified receptor in detergent solution
Bimane-labeled and Atto-labeled receptors were used at respective concentrations of 0.2μM 
and 0.1μM in buffer containing 20mM Hepes pH 7.4, 100mM NaCl, 0.02% (w/v) DDM and 
0.002% (w/v) cholesterol hemisuccinate. Salmeterol and epinephrine stocks were prepared 
as 50mM and 100mM solutions in DMSO and added at indicated final concentrations. 
Ligand concentrations were chosen to achieve saturation of detergent-solubilized receptor. 
To avoid any non-specific vehicle effects, care was taken to obtain the same final 
concentration of DMSO in all samples. Where indicated, Gs was added to a final 
concentration of 2μM. To allow efficient ligand binding and full equilibration, samples were 
incubated at the final concentrations used for 1 hour in the dark prior to measurements. 
Fluorescence data was collected in a quartz cuvette with 500μL of sample using 
FluorEssence v3.8 software on a Fluorolog instrument (Horiba) in photon counting mode. 
Bimane fluorescence was measured by excitation at 370nm with excitation and emission 
bandwidth passes of 4nm, and emission spectra were recorded from 410 to 510 nm in 1nm 
increments and 1s integration time. Atto fluorescence was measured by excitation at 650nm 
with excitation and emission bandwidth passes of 5nm, and emission spectra were recorded 
from 660 to 730 nm in 1nm increments and 1s integration time. Measurements were 
performed in triplicate.
Radioligand binding assays
Binding curves were obtained by incubating the DDM purified wild-type, bimane- and 
Atto655-labeled receptors in the presence of M1 FLAG–sepharose and 2 mM Ca2+, under 
shaking at room temperature for 1.5h. The antagonist [3H]-dihydroalprenolol (DHA) 
(PerkinElmer) was used to obtain saturation binding curves. Competition binding 
measurements for salmeterol and epinephrine were performed in a similar way, using DHA 
at a concentration slightly above Kd, as determined by saturation binding. Non-specific 
binding was accounted for by measuring in the presence of 10μM cold alprenolol. Beads 
were harvested using a 48-well Brandell harvester and counted in a LS6000TA scintillator 
(Beckman) using Cytoscint (MP Biomedical).
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Statistical Analysis.
Statistical significance of hydrogen bond duration from MD trajectories (Fig. 5a) was 
assessed using the one-sided Welch’s unequal variances t-test. Statistical significance of the 
binding affinities (Supplementary Table 1) was assessed using Ordinary One-way ANOVA 
(Tukey) test at a multiplicity adjusted P value = 0.05. Statistical significance of the fitted 
mean logKi values (Supplementary Fig. 1) was assessed using a one-way ANOVA Tukey 
test at a P values of 0.05 (adjusted for multiple comparisons).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1: Crystal structure of salmeterol-bound β2AR.
a.Chemical structures of β2AR ligands: partial agonists salmeterol and salbutamol; full 
agonists epinephrine and BI-16707. The respective pharmacophores that bind the orthosteric 
ligand binding pocket are highlighted in purple, and the aryloxyalkyl tail of salmeterol, 
which binds the exosite, is highlighted in blue. b. Overall ribbon representation of the 
salmeterol-bound β2AR – Nb71 complex structure. The T4L lysozyme fusion facilitates 
crystallization, while Nb71 stabilizes the active, salmeterol-bound (orange spheres) β2AR. c. 
Cross-section through the receptor, with the interior in black, highlighting salmeterol 
(orange spheres) occupying the orthosteric site and the exosite.
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Figure 2: Structural features of the β2AR-salmeterol-Nb71 complex.
a,b,c. Overlay of inactive carazolol bound receptor (grey), Nb71 and salmeterol bound 
β2AR (purple) and the BI-167107 bound β2AR - Gs complex (green and pink, respectively). 
a. Side view (inset) and cytoplasmic view of TM6, showing the position of TM6 relative to 
the helical bundle. The extent of TM6 movement, indicated by black arrows, was measured 
using the Cα of Glu268 as reference point. b. Rearrangement of Pro2115.50, Ile1213.40 and 
Phe2826.44 and the associated outward movement of the cytoplasmic end of TM6. The 
inactive structure of β2AR is colored silver. The active structures of β2AR are colored blue 
(coupled with salmeterol and Nb71), cyan (coupled with epinephrine and 6B9) and green 
(coupled with BI-167107 and Gs). c. Extracellular (top) view of β2AR, with major 
conformational changes between structures indicated by red arrows and ligands in stick 
representation.
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Figure 3: Salmeterol exosite and receptor subtype-selectivity determinants.
a. Side and b. top view of β2AR, with stick representation of salmeterol (orange). c. 
Spherical representation of the salmeterol aryloxyalkyl moiety (orange) and the β2AR 
(blue). d. Residues important for interaction and specificity are highlighted in yellow and 
labeled. With the exception of Y308 (indicated by a red arrow), the amino acids that form 
the orthosteric binding pocket for epinephrine are identical between β1AR and β2AR. e. 
Comparison of the ligand binding sites between β2AR (left panel) bound to salmeterol 
(orange sticks) and M2R (right panel) bound to the allosteric modulator LY2119620 (green 
sticks).
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Figure 4: Hydrogen bond interactions in the orthosteric site and re-arrangement of the ligand 
binding pocket.
Comparison of ligand-mediated hydrogen bonds (black dashed lines) in a. epinephrine-
bound and b. salmeterol-bound β2AR.
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Figure 5: Ligands and specific residues in the orthosteric site modulate hydrogen bonding and 
signaling outcome.
a. Frequency of hydrogen bonding between Ser2035.42 / Asn2936.55 and the ligand m-OH 
group, Ser2075.46 and the ligand p-OH group, and Asn3127.39 and the ligand β-OH group in 
MD simulations of receptor bound to epinephrine or salmeterol. Individual datapoints (black 
dots) and SEM (error bars) of 3 independent experiments are shown. Statistical significance 
was assessed using the one-side Welch’s unequal variances t-test (p values: 
Ser2035.42=0.00003; Ser2075.46=0.08; Asn2936.55=0.004; Asn3127.39=0.01). The actual 
statistical significance of the differences (e.g. for Ser207) may be better than computed, as 
each of the data points is based on a trajectory with thousands of samples. b,c. BRET-based 
assays monitoring β-arrestin2 recruitment and G-protein activation on wild-type and mutant 
β2AR constructs. Data represent the mean (symbols) ± SEM (error bars) of 3 independent 
experiments. Error bars shorter than the height of the symbol are not shown.
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Figure 6: Spectroscopic interrogation of ligand-induced changes in TM6 conformation on 
detergent-solubilized, purified labeled receptor.
a,c. Schematic representation of labeled receptor constructs used to probe the outward 
motion of TM6. The β2AR transmembrane helices 1–5 and 7 are shown as grey cylinders. 
The blue cylinders represent TM6 in the inactive (light blue) and active (dark blue) 
conformation, with the labels attached at the intracellular end of TM6 depicted according to 
their overall structure. The bimane fluorophore (teal) is an environment-sensitive reporter, 
while the Atto655 dye (pink) is quenched in a distance-dependent way by an engineered 
tryptophan (L230W, in yellow). b,d. Steady-state fluorescence emission spectra of bimane-
labeled and Atto655-labeled receptor in the presence of epinephrine or salmeterol. The 
spectra are normalized relative to unliganded receptor (apo, light blue curve) and show the 
fluorescence dose-response of receptor up to saturating ligand concentrations, in the absence 
and presence of G protein. Data is plotted as mean (curves) and standard deviation (error 
bars) of triplicate measurements.
Masureel et al. Page 25
Nat Chem Biol. Author manuscript; available in PMC 2019 April 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
